Stryker Pushes For Changes To Stroke Care After DAWN
Stryker's Trevo Retriever is the first stent retriever approved by US FDA as a front-line treatment for patients experiencing acute ischemic stroke up to 24 hours from symptom onset, matching the time window recommended in the latest professional treatment guidelines. Now, the company is trying to help the stroke-care system in the US catch up to the science.
You may also be interested in...
Results of the DEFUSE 3 trial presented at the International Stroke Conference in Los Angeles, along with the previously announced DAWN trial results, support a new recommendation in the American Heart Association/American Stroke Association guidelines on early management of acute ischemic stroke, extending the viable treatment window from six hours to 24 hours in some patients. The change could drive thrombectomy uptake and an aspiration-first approach.
Results of the DAWN trial show that endovascular thrombectomy with Stryker's Trevo produces better outcomes than medication alone when used in certain patients who experienced an ischemic stroke. The results could provide a boost to Stryker as well as Stryker's competitors in the mechanical thrombectomy market, including Medtronic, Penumbra.